公開(公告)號
|
CN1436234A
|
公開(公告)日
|
2003.08.13
|
申請(專利)號
|
CN01806526.0
|
申請日期
|
2001.01.16
|
專利名稱
|
用于前列腺癌治療和診斷的組合物及方法
|
主分類號
|
C12N15/12
|
分類號
|
C12N15/12;C12N15/11;C12N1/21;C12N5/10;C07K14/47;C07K16/18;C07K19/00;A61K38/17;A61K48/00;G01N33/68;C12Q1/68;C12N5/08
|
分案原申請?zhí)? |
|
優(yōu)先權(quán)
|
2000.1.14 US 09/483,672
|
申請(專利權(quán))人
|
科里克薩有限公司
|
發(fā)明(設(shè)計)人
|
徐江春;D·C·迪隆;J·L·密特查姆
|
地址
|
美國華盛頓州
|
頒證日
|
|
國際申請
|
PCT/US01/01574 2001.1.16
|
進(jìn)入國家日期
|
2002.09.13
|
專利代理機(jī)構(gòu)
|
中國國際貿(mào)易促進(jìn)委員會專利商標(biāo)事務(wù)所
|
代理人
|
唐偉杰
|
國省代碼
|
美國;US
|
主權(quán)項
|
一種分離的多核苷酸,其含有選自下列的序列:(a)SEQ ID NO:1-111,115-171,173-175,177,179-305,307-315,326,328,330,332-335,340-375,381,382和384-476,524,526,530,531,533,535,536,552,569-572,587,591,593-606,618-626,630,631,634,636,639-655,674,680,681,711,713,716,720-722,735,737-739,751,753,764,765,773-776和786-788所示的序列;(b)SEQ ID NO:1-111,115-171,173-175,177,179-305,307-315,326,328,330,332-335,340-375,381,382和384-476,524,526,530,531,533,535,536,552,569-572,587,591,593-606,618-626,630,631,634,636,639-655,674,680,681,711,713,716,720-722,735,737-739,751,753,764,765,773-776和786-788所示序列的互補序列;(c)由SEQ ID NO:1-111,115-171,173-175,177,179-305,307-315,326,328,330,332-335,340-375,381,382和384-476,524,526,530,531,533,535,536,552,569-572,587,591,593-606,618-626,630,631,634,636,639-655,674,680,681,711,713,716,720-722,735,737-739,751,753,764,765,773-776和786-788所示序列的至少20個連續(xù)殘基組成的序列;(d)在中度嚴(yán)格條件下可與SEQ ID NO:1-111,115-171,173-175,177,179-305,307-315,326,328,330,332-335,340-375,381,382和384-476,524,526,530,531,533,535,536,552,569-572,587,591,593-606,618-626,630,631,634,636,639-655,674,680,681,711,713,716,720-722,735,737-739,751,753,764,765,773-776和786-788所示序列雜交的序列;(e)與SEQ ID NO:1-111,115-171,173-175,177,179-305,307-315,326,328,330,332-335,340-375,381,382和384-476,524,526,530,531,533,535,536,552,569-572,587,591,593-606,618-626,630,631,634,636,639-655,674,680,681,711,713,716,720-722,735,737-739,751,753,764,765,773-776和786-788所示序列有至少75%同一性的序列;(f)與SEQ ID NO:1-111,115-171,173-175,177,179-305,307-315,326,328,330,332-335,340-375,381,382和384-476,524,526,530,531,533,535,536,552,569-572,587,591,593-606,618-626,630,631,634,636,639-655,674,680,681,711,713,716,720-722,735,737-739,751,753,764,765,773-776和786-788所示序列有至少90%同一性的序列;和(g)SEQ ID NO:1-111,115-171,173-175,177,179-305,307-315,326,328,330,332-335,340-375,381,382和384-476,524,526,530,531,533,535,536,552,569-572,587,591,593-606,618-626,630,631,634,636,639-655,674,680,681,711,713,716,720-722,735,737-739,751,753,764,765,773-776和786-788所示序列的簡并變體。
|
摘要
|
公開了用于治療和診斷癌癥(特別是前列腺癌)的組合物和方法。說明性組合物含有一種或多種前列腺特異的多肽、其免疫原部分、編碼這些多肽的多核苷酸、表達(dá)這些多肽的抗原遞呈細(xì)胞,和對于表達(dá)這些多肽的細(xì)胞特異的T細(xì)胞。例如,公開的這些組合物可用于診斷、預(yù)防和/或治療疾病,特別是前列腺癌。
|
國際公布
|
WO01/51633 英 2001.7.19
|